O
Oncoinvent ASA
OSE:ONCIN
Oncoinvent ASA
OSE:ONCIN
Price:
43.3
NOK
0.12%
Market Closed
Market Cap:
kr195.1m
Balance Sheet
Balance Sheet Decomposition
Oncoinvent ASA
Oncoinvent ASA
Balance Sheet Decomposition is not available for
Oncoinvent ASA
Oncoinvent ASA
Balance Sheet
Oncoinvent ASA
Oncoinvent ASA
Currency: NOK
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
74
|
162
|
370
|
360
|
254
|
722
|
437
|
151
|
156
|
140
|
|
| Cash Equivalents |
74
|
162
|
370
|
360
|
254
|
722
|
437
|
151
|
156
|
140
|
|
| Total Receivables |
0
|
0
|
13
|
17
|
15
|
14
|
12
|
14
|
10
|
9
|
|
| Accounts Receivables |
0
|
0
|
12
|
17
|
13
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
1
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
8
|
12
|
0
|
0
|
0
|
1
|
1
|
2
|
7
|
6
|
|
| Total Current Assets |
82
|
174
|
384
|
378
|
269
|
736
|
449
|
167
|
174
|
155
|
|
| PP&E Net |
0
|
0
|
1
|
1
|
1
|
2
|
1
|
0
|
0
|
1
|
|
| PP&E Gross |
0
|
0
|
1
|
1
|
1
|
2
|
1
|
0
|
0
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
1
|
1
|
2
|
3
|
4
|
5
|
5
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
82
N/A
|
175
+112%
|
384
+120%
|
379
-1%
|
270
-29%
|
738
+173%
|
450
-39%
|
167
-63%
|
174
+5%
|
156
-11%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
5
|
11
|
22
|
24
|
27
|
23
|
27
|
30
|
19
|
13
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
37
|
36
|
48
|
28
|
19
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
|
| Other Current Liabilities |
7
|
11
|
12
|
18
|
24
|
6
|
1
|
0
|
0
|
0
|
|
| Total Current Liabilities |
12
|
21
|
34
|
42
|
51
|
67
|
65
|
78
|
47
|
32
|
|
| Long-Term Debt |
1
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
1
|
|
| Other Liabilities |
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
18
N/A
|
21
+21%
|
34
+60%
|
42
+22%
|
51
+22%
|
68
+34%
|
66
-3%
|
78
+19%
|
47
-40%
|
33
-29%
|
|
| Equity | |||||||||||
| Common Stock |
2
|
3
|
5
|
5
|
6
|
9
|
9
|
9
|
269
|
39
|
|
| Retained Earnings |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
189
|
22
|
|
| Additional Paid In Capital |
50
|
132
|
325
|
310
|
188
|
628
|
335
|
36
|
1
|
9
|
|
| Other Equity |
12
|
18
|
20
|
22
|
26
|
33
|
40
|
44
|
47
|
53
|
|
| Total Equity |
65
N/A
|
153
+137%
|
350
+129%
|
337
-4%
|
220
-35%
|
670
+205%
|
384
-43%
|
88
-77%
|
127
+44%
|
123
-4%
|
|
| Total Liabilities & Equity |
82
N/A
|
175
+112%
|
384
+120%
|
379
-1%
|
270
-29%
|
738
+173%
|
450
-39%
|
167
-63%
|
174
+5%
|
156
-11%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
25
|
34
|
50
|
55
|
62
|
761
|
8
|
8
|
27
|
39
|
|
Switch to:
Switch to:
See Also
Discover More
